Abbreviated name: DLL4
Compound class:
Endogenous peptide in human, mouse or rat
Comment: DLL4 is a 685 amino acid, peptide Notch receptor ligand expressed on the membranes of vascular endothelial cells [4]. DLL4 is a molecular target for the development of anti-cancer therapies [3].
Species: Human
|
No information available. |
Mechanism Of Action and Pharmacodynamic Effects |
The Notch signaling pathway is an intracellular signaling system that plays a critical role in embryonic development, tissue repair, hematopoiesis, the maintenance of endothelial and gut epithelial stem cell homeostasis and cellular survival [2,5]. In addition to aberrant Notch signalling being involved in malignant transformation, this pathway also plays an important role in the maintenance of cancer stem cells. These observations make inhibition of Notch signalling an attractive anti-cancer hypothesis. Demcizumab targets DLL4 which is one of the key ligands in this pathway. |